

**A. For Equity Issues**

<b>Name of the issue: APTUS PHARMA LIMITED</b>						
1 <b>Type of issue (IPO/ FPO)</b>	Initial Public Offering (IPO) on SME Platform of BSE					
2 <b>Issue size (Rs. crore)</b>	1302.00					
3 <b>Grade of issue alongwith name of the rating agency</b>	Since the issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, there is no requirement of appointing a IPO Grading agency.					
4 <b>Subscription level (number of times), If the issue was undersubscribed, please clarify how the funds were arranged.</b>	41.04 times					
<b>5 QIB holding (as a % of total outstanding capital) as disclosed to stock exchanges (See Clause 35 of the listing agreement)</b>						
(i) <b>allotment in the issue</b>	Nil					
(ii) <b>at the end of the 1st Quarter immediately after the listing of the issue</b>	Nil					
(iii) <b>at the end of 1st FY</b>	Nil					
(iv) <b>at the end of 2nd FY</b>	Nil					
(v) <b>at the end of 3rd FY</b>	Nil					
*Will be updated once the company makes necessary disclosures on the website of BSE Ltd						
<b>6 Financials of the issuer (as per the annual financial results submitted to stock exchanges under Clause 41 of the listing agreement)</b>						
(Rs. in Lakhs)						
<b>Parameters</b>	<b>1st FY (2025-26)</b>	<b>2nd FY (2026-27)</b>	<b>3rd FY (2027-28)</b>			
Income from operations	Will update the same at the endof 1st Year	Will update the same at the endof 2nd Year	Will update the same at the endof 3rd Year			
Net Profit for the period						
Paid-up equity share capital						
Reserves excluding revaluation reserves						
<b>7 Trading status in the scrip of the issuer (whether frequently traded (as defined under Regulation 2 (i) of SEBI (SAST) Regulations, 2011) or infrequently traded/ delisted/ suspended by any stock exchange, etc.)</b>						
(i) <b>at the end of 1st FY</b>	Will update the same at the endof 1st Year					
(ii) <b>at the end of 2nd FY</b>	Will update the same at the endof 2nd Year					
(iii) <b>at the end of 3rd FY</b>	Will update the same at the endof 3rd Year					
<b>8 Change, if any, in directors of issuer from the disclosures in the offer document (See Clause 30 of the listing agreement)</b>						
(i) <b>at the end of 1st FY</b>	Will update the same at the endof 1st Year					
(ii) <b>at the end of 2nd FY</b>	Will update the same at the endof 2nd Year					
(iii) <b>at the end of 3rd FY</b>	Will update the same at the endof 3rd Year					
<b>9 Status of implementation of project/ commencement of commercial production (as submitted to stock exchanges under Clause 41 (IV) (e) of the listing agreement)</b>						
(Rs. In Lacs)						
<b>Objects of the issue (Rs in Lacs)</b>	<b>as disclosed in the offer document</b>	<b>Actual implementation*</b>	<b>Reasons for delay in implementation, if any</b>			
Capital Expenditure for Office Premises with Furniture and Industrial Racks	162.95	163	NA			
Working Capital	800.00		NA			
General corporate purposes	191.05					
<b>TOTAL</b>	<b>1,154.00</b>		NA			
*Source: BSE filing Reg 32(1) of SEBI(LODR) Reg, 2015						
<b>10 Status of utilization of issue proceeds (as submitted to stock exchanges under Clauses 41, 43 and 43A of the listing agreement)</b>						
(Rs. In Lacs)						
(i) <b>as disclosed in the offer document</b>	1,154					
(ii) <b>Actual utilization</b>	NA					
(iii) <b>Reasons for deviation, if any</b>	NA					
<b>11 Comments of monitoring agency, if applicable (See Regulation 16 of SEBI (ICDR) Regulations, 2009 read with Clause 43A of the listing agreement)</b>						
(a) <b>Comments on use of funds</b>	NA					
(b) <b>Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document</b>						
(c) <b>Any other reservations expressed by the monitoring agency about the end use of funds</b>						
(To be submitted till the time the issue proceeds have been fully utilised)						
<b>12 Price- related data</b>						
<b>Issue price (Rs):</b>	70					
<b>Price parameters</b>	<b>At close of listing day 30-09-2025</b>	<b>At close of 30th calendar day from listing day</b>	<b>At close of 90th calendar day from listing day</b>	<b>As at the end of 1st FY after the listing of the issue</b>	<b>As at the end of 2nd FY after the listing of the issue</b>	<b>As at the end of 3rd FY after the listing of the issue</b>
Market Price	84.84	138.30	will update after 90th days	Closing price	High (during the FY)	Low (during the FY)
Index (of the Designated Stock Exchange):	80,267.62	84,997.13	will update after 90th days	Will update the same at the endof 1st Year	Will Update the same at the end of 2nd Year	Will update the same at the end of 3rd Year
Sectoral Index (mention the index that has been considered and reasons for considering the same)	-	-	-			
*No sectoral index available						
<b>13 Basis for Issue Price and Comparison with Peer Group &amp; Industry Average</b> (Source of accounting ratios of peer group and industry average may be indicated: source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated)						
<b>Accounting ratio</b>	<b>Name of company</b>	<b>As disclosed in the offer document (See Clause 2 (VII) (K) of Schedule VII to SEBI (ICDR) Regulations (2009)</b>	<b>At the end of 1st FY</b>	<b>At the end of 2nd FY</b>	<b>At the end of 3rd FY</b>	
<b>EPS</b>	APTUS PHARMA LIMITED	5.32				
	Zota health care limited	3.16				
	Sunrest Lifescience Limited	4.66				
	Lincoln Pharmaceuticals Limited	41.11				
Industry Avg:	16.31					
<b>P/E</b>	APTUS PHARMA LIMITED	13.16				
	Zota health care limited	382.12				
	Sunrest Lifescience Limited	40.56				
	Lincoln Pharmaceuticals Limited	13.53				
Industry Avg:	135.40	Will update the same at the endof 1st Year	Will update the same at the endof 2nd Year	Will update the same at the end of 3rd year		
<b>RoNW</b>	APTUS PHARMA LIMITED	44.50				
	Zota health care limited	2.72				
	Sunrest Lifescience Limited	12.36				
	Lincoln Pharmaceuticals Limited	12.26				
Industry Avg:	9.11					
<b>NAV per share based on balance sheet</b>	APTUS PHARMA LIMITED	13.89				
	Zota health care limited	110.83				
	Sunrest Lifescience Limited	37.72				
	Lincoln Pharmaceuticals Limited	335.34				
Industry Avg:	161.30					
*Note: There is no company in peer group with the Type of business with which the company is operating.						
<b>14 Any other material information</b> Nil						

**Note:**

- (i) Merchant Banker can give its comments on any of the above sections
- (ii) Merchant Banker may obtain information/clarification from the issuer or stock exchange, wherever felt necessary
- (iii) In case any of the above reporting dates happens to be a holiday, the immediately following working day may be taken